INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 203 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,070,417 | -16.2% | 2,751,018 | -3.9% | 0.00% | – |
| Q2 2023 | $1,277,544 | -69.9% | 2,861,243 | -44.7% | 0.00% | -100.0% |
| Q1 2023 | $4,244,960 | +55549.7% | 5,176,781 | +5.9% | 0.00% | 0.0% |
| Q4 2022 | $7,628 | -99.9% | 4,890,119 | +6.3% | 0.00% | 0.0% |
| Q3 2022 | $7,935,000 | +15.7% | 4,600,017 | +16.1% | 0.00% | 0.0% |
| Q2 2022 | $6,856,000 | -43.7% | 3,963,556 | +16.8% | 0.00% | -50.0% |
| Q1 2022 | $12,180,000 | -33.6% | 3,393,033 | -7.7% | 0.00% | 0.0% |
| Q4 2021 | $18,336,000 | -22.9% | 3,674,626 | +10.6% | 0.00% | -33.3% |
| Q3 2021 | $23,793,000 | -29.2% | 3,323,169 | -8.3% | 0.00% | -40.0% |
| Q2 2021 | $33,589,000 | +9.0% | 3,623,488 | +9.1% | 0.01% | 0.0% |
| Q1 2021 | $30,817,000 | +37.9% | 3,320,869 | +31.6% | 0.01% | +25.0% |
| Q4 2020 | $22,340,000 | -19.6% | 2,524,403 | +5.4% | 0.00% | -20.0% |
| Q3 2020 | $27,787,000 | -52.8% | 2,395,449 | +9.8% | 0.01% | -61.5% |
| Q2 2020 | $58,816,000 | +369.3% | 2,182,420 | +29.6% | 0.01% | +333.3% |
| Q1 2020 | $12,532,000 | +40.6% | 1,684,463 | -37.7% | 0.00% | +200.0% |
| Q4 2019 | $8,912,000 | +236.3% | 2,702,162 | +109.0% | 0.00% | 0.0% |
| Q3 2019 | $2,650,000 | -24.8% | 1,292,685 | +7.8% | 0.00% | 0.0% |
| Q2 2019 | $3,526,000 | -16.4% | 1,199,559 | +6.0% | 0.00% | 0.0% |
| Q1 2019 | $4,219,000 | -47.5% | 1,131,213 | -43.7% | 0.00% | 0.0% |
| Q4 2018 | $8,032,000 | +64.4% | 2,008,190 | +128.4% | 0.00% | 0.0% |
| Q3 2018 | $4,887,000 | +46.4% | 879,129 | +3.2% | 0.00% | 0.0% |
| Q2 2018 | $3,338,000 | -12.0% | 851,738 | +5.8% | 0.00% | 0.0% |
| Q1 2018 | $3,792,000 | +10.2% | 805,301 | -3.4% | 0.00% | 0.0% |
| Q4 2017 | $3,442,000 | -28.1% | 833,627 | +10.5% | 0.00% | -50.0% |
| Q3 2017 | $4,784,000 | +4.6% | 754,626 | +29.3% | 0.00% | 0.0% |
| Q2 2017 | $4,575,000 | +23.4% | 583,657 | +4.2% | 0.00% | 0.0% |
| Q1 2017 | $3,708,000 | +7.3% | 560,164 | +12.5% | 0.00% | 0.0% |
| Q4 2016 | $3,456,000 | -23.5% | 498,119 | +2.8% | 0.00% | 0.0% |
| Q3 2016 | $4,515,000 | +2.3% | 484,461 | +1.5% | 0.00% | 0.0% |
| Q2 2016 | $4,412,000 | +5.2% | 477,534 | -0.8% | 0.00% | 0.0% |
| Q1 2016 | $4,193,000 | +43.0% | 481,434 | +10.3% | 0.00% | 0.0% |
| Q4 2015 | $2,932,000 | +18.6% | 436,511 | +2.1% | 0.00% | +100.0% |
| Q3 2015 | $2,472,000 | -27.8% | 427,687 | +1.9% | 0.00% | -50.0% |
| Q2 2015 | $3,426,000 | +22.2% | 419,900 | +22.2% | 0.00% | 0.0% |
| Q1 2015 | $2,803,000 | -7.9% | 343,586 | +3.6% | 0.00% | 0.0% |
| Q4 2014 | $3,044,000 | -5.4% | 331,707 | +1.5% | 0.00% | 0.0% |
| Q3 2014 | $3,219,000 | -1.0% | 326,958 | +8.7% | 0.00% | 0.0% |
| Q2 2014 | $3,252,000 | – | 300,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |